Advertisement
Advertisement

CNSP

CNSP logo

Cns Pharmaceuticals Inc

0.1127
USD
+0.0007
+0.63%
Dec 18, 15:51 UTC -5
Closed
...

Cns Pharmaceuticals Inc Profile

About

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is based in Houston, United States.

Info & Links

CEO

John Climaco

Headquarters

2100 WEST LOOP SOUTH, SUITE 900
HOUSTON, TX 77027, UNITED STATES

Auditor

MaloneBailey, LLP

Share holders

11,500

Employees

5

Cns Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

6.48M

Enterprise Value

-462.78K

Enterprise Value/EBITDA(ttm)

0.03

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.03

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

93.01%

Return on Assets(ttm)

-515.32%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-17.08M

Net Income Available to Common(ttm)

-17.06M

Diluted EPS(ttm)

-74.97

Share Statistics

Beta (5Y Monthly)

2.55

52-Week Change

-99.90%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

57.49M

Dividend Yield

0.00%

Float4

57.45M

% Held by Insiders

0.07%

% Held by Institutions

14.02%

Balance Sheet

Total Cash(mrq)

6.97M

Total Cash Per Share(mrq)

0.12

Total Debt(mrq)

31.20K

Total Debt/Equity(mrq)

0.93%

Current Ratio(mrq)

1.82%

Quick Ratio(mrq)

1.82%

Book Value Per Share(mrq)

0.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.52

Free Cash Flow(ytd)

-11.64M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement